Hilliard & Shadowen’s attorneys have been representing clients in national antitrust cases for more than 20 years, with a commitment to providing economic justice to those who fall victim to anticompetitive conduct. The firm’s antitrust attorneys especially served pivotal roles challenging several pervasive anticompetitive practices throughout the pharmaceutical industry. Most notable is the firm’s founding partner, Steve Shadowen, whose victories challenging “pay for delay” patent settlements led the American Antitrust Institute to award Mr. Shadowen its national accolade for Outstanding Antitrust Litigation Achievement in Private Law Practice.
Courts consistently recognize the excellence of Hilliard & Shadowen, appointing the firm as co-lead counsel in major antitrust class action lawsuits that seek to recover hundreds of millions of dollars in damages. Below provides information about representative cases in which Hilliard & Shadowen plays a significant part.
November 12thView all News
FILED: April 15, 2013
Hilliard & Shadowen is co-lead counsel on behalf of a proposed class of end-payors against AbbVie for allegedly entering into unlawful agreements to delay the market entry of generic substitutes of its lipid disorder drug, Niaspan.
FILED: December 31, 2013
Hilliard & Shadowen is lead counsel representing end-payors against Takeda alleging that it engaged in anticompetitive conduct that blocked competitive threats to its two blockbuster anti-diabetic drugs, ACTOS and ACTOplus Met.
FILED: November 20, 2013
Hilliard & Shadowen has filed a complaint on behalf of a proposed class of end-payors alleging defendants’ entered into an anticompetitive “pay for delay” agreement that delayed the market entry of a lower-priced generic equivalent for the drug, Aggrenox.
FILED: November 12, 2013
Hilliard & Shadowen, along with its co-counsel, represent a proposed class of end-payors in a case against Teikoku Pharma USA for allegedly entering into unlawful agreements with potential competitors to delay the market entry of generic substitutes of the pain patch, Lidoderm.
FILED: August 24, 2012
Hilliard & Shadowen is co-lead counsel representing a class of end-payors and consumers alleging that AstraZeneca entered into unlawful agreements to delay competing generic substitutes of its heartburn-drug Nexium, preserving for AstraZeneca up to approximately $3 billion per year in monopoly revenue.
FILED: March 1, 2013
Hilliard & Shadowen is co-lead counsel on behalf of a proposed class of end-payors against Reckitt Benckiser, alleging that the company engaged in anticompetitive strategies to preserve its monopoly over its addiction-treatment drug, Suboxone.
FILED: July 22, 2013
Hilliard & Shadowen represents a proposed class of end-payors against Medicis for alleged anticompetitive conduct in an effort to prevent patients from receiving lower priced generic equivalents to Solodyn at the pharmacy.
FILED: April 5, 2013
Hilliard & Shadowen is co-lead counsel in a class action alleging Warner Chilcott provided payments to competitors in exchange for their agreements to settle their lawsuits threatening the validity of a patent covering Loestrin 24 Fe and to refrain from marketing generic substitutes of the contraceptive drug for nearly the entire life of the patent.